A pilot study of high dose allopurinol in the management of gout:

Completed

• Conditions: Gout; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12606000276550
• Lead Sponsor: isa Stamp

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-07-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Patients fulfil the diagnostic criteria of gout (Wallace, Robinson et al. 1977) which are as follows Clinical diagnosis of gout requires either A, B, or C to be metA. The presence of characteristic urate crystals in the joint fluidB. A tophus proved to contain urate crystals by chemical means or polarised light microscopyC. The presence of 6 of the following 12 clinical laboratory, and x-ray phenomenaI. Maximum inflammation developed within one dayII. More than one attack of acute arthritisIII. Attack of monoarthritisIV. Redness observed over the affected joint(s)V. First metatarsophalangeal joint painful or swollenVI. Unilateral first metatarsophalangeal joint attackVII. Unilateral attack involving tarsal jointVIII. Suspected tophusIX. HyperuricaemiaX. Asymmetric swelling within a joint XI. Subcortical cysts without erosionsXII. Negative culture of joint fluid for microorganisms during attack of joint inflammation. 2. Subjects are willing and able to participate in the study and from whom written informed consent has been obtained.

Exclusion Criteria

1. History of adverse effects with use of allopurinol.2. Patients currently taking azathioprine3. Patients with a solid organ transplant (eg kidney, liver or heart transplant)4. Presence of chronic infection or other severe concomitant medical illness or psychiatric disease.5. Pregnant or breast-feeding females and female subjects of child bearing age who are not practising medically approved methods of contraception.6. HIV positive patients.7. History of drug abuse that would interfere with the ability to comply with the study protocol.8. Patients with active, concomitant malignancies.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum urate[At each month visit]

Secondary Outcome Measures

Name	Time	Method
umber of gouty attacks during the study period.[12 months of study]